The proton therapy was started to use since 2015 November after 6 patients and one- year safety observation clinical registration study. There were four gantries installed; two are conventional passive scanning beam and the other are pencil scanning beam. The pencil beam was started to serve patients since 2016/Dec. One of the passive scanning beam gantries was upgraded to pencil beam since 2019/Jan and planned to use in 2020.
　　There had been more than 2,000 patients received proton therapy. The majority of patients are hepatoma (23.7%), head and neck (20.1%) Brain (including pediatrics, 14.6%) breast (9.4%) and lung (9.7%). The prostate cancer patients just only 1%.
　　The local tumor control for hepatoma after proton therapy is 90.6% at two year follow-up. More than half (58.7%) are recurrent disease with median 5.5 cm tumor. The median age of patients is 66.8 (+/- 11.8). The local tumor control does not relate to age, tumor size and tumor invasion to vessel or not. Only 2 patients had grade IV and no grade V complication noted.
　　In head and neck including NPC cancer patients, there are significantly difference in feeding tube insertion, body weight loss, hematology complications and admission rate between proton therapy and photon therapy. There are both in trend that proton therapy had better survival outcome. Proton therapy also had better patient reported outcome in health-related quality of life in both diseases.
　　There are also found that decrease complications in breast cancer, brain tumor and pediatric cancer patients.
　　The more detail will be presented.